Curagen Corporation

Amgen Fremont Inc.

Celldex Therapeutics Limited

Michael Jeffers

Henri Lichenstein

William LaRochelle

Richard August Shimkets

Peter S Mezes

John L Herrmann

Kam Fai Tse

Ian Nevin Foltz

Gregory M Landes

Francine Zhifen Chen

Meijia Yang

Ferenc L Boldog

Catherine Burgess

Sudhirdas K Prayaga

Binyam Bezabeh

Elma Fernandes

Mehdi Mesri

Gary Starling

Nikolia Khramtsov

Orit Foord

Xiao-Chi Jia

Michael Torgov

Meina Liang

Scott L Klakamp

Luca Rastelli

Muralidhara Padigaru

William Grosse

Denise M Lepley

Linda L Gorman

Daniel K Rieger

John P Alsobrook, Ii

Carol E A Pena

Juan Davagnino

Mei Zhong

Cyrus Karkaria

Henry Lichenstein

Andrei Chapoval

Gulshan Ara

Vincent A Pollack

Feng Xiao

Francine Chen

Kam Fei Tse

The invention described herein is related to antibodies directed to the antigen TIM-1 and uses of such antibodies. In particular, there are provided fully human monoclonal antibodies directed to the antigen TIM-1. Isolated polynucleotide sequences encoding, and amino acid sequences comprising, heavy and light chain immunoglobulin molecules, particularly sequences corresponding to contiguous heavy and light chain sequences spanning the framework regions (FR's) and/or complementarity determining regions (CDR's), specifically from FR1 through FR4 or CDR1 through CDR3, are provided. Hybridomas or other cell lines expressing such immunoglobulin molecules and monoclonal antibodies are also provided.

Antibodies against T cell immunoglobulin domain and mucin domain 1 (TIM-1) antigen and uses thereof

The present invention provides fully human monoclonal antibodies that specifically bind to GPNMB, and uses thereof. Nucleotide sequences encoding, and amino acid sequences comprising, heavy and light chain immunoglobulin molecules, particularly sequences corresponding to contiguous heavy and light chain sequences spanning the framework regions and/or complementarity determining regions (CDRs) are provided. The present invention also provides immunoconjugates comprising anti-GPNMB antibodies and methods of using such immunoconjugates. The present invention further provides bi-specific antibodies comprising an anti-GPNMB antibody component and an anti-CD3 component, and methods of using such bispecific antibodies.

Antibodies directed to GPNMB and uses thereof

The present invention provides FGF-CX, a novel isolated polypeptide, as well as a polynucleotide encoding FGF-CX and antibodies that immunospecifically bind to FGF-CX or any derivative, variant, mutant, or fragment of the FGF-CX polypeptide, polynucleotide or antibody. The invention additionally provides methods in which the FGF-CX polypeptide, polynucleotide and antibody are used in detection and treatment of a broad range of pathological states, as well as other uses.

Polypeptides of FGF-CX

The present invention is based upon methods of treating inflammatory conditions in the intestinal tract of mammals using growth factor related polypeptides. The invention includes methods of reducing the mortality rate or delaying mortality in a subject suffering from an inflammatory pathology. Methods of using fibroblast growth factor-CX (FGF-CX) polynucleotides sequences and the FGF-CX polypeptides encoded by such nucleic acid sequence, or variants, fragments and homologs thereof, are claimed in the invention. Similarly, methods of using FCTRX polynucleotide sequences and the FCTRX polypeptides encoded by such nucleic acid sequences, or variants, fragments and homologs thereof, alone or in combination, are also claimed in the invention. FCTRX collectively refers to any of six variant FCTRX sequences, variously designated FCTR1, FCTR2, FCTR3, FCTR4, FCTR5 and FCTR6.

Treatment of inflammatory bowel disease using fibroblast growth factor CX polypeptides

The present invention provides FGF-CX polypeptides and polynucleotides, and antibodies that immunospecifically bind to FGF-CX or any derivative, variant, mutant, or fragment of the FGF-CX polypeptide, polynucleotide or antibody. The invention additionally provides methods of use for the FGF-CX polypeptide, polynucleotide and antibody.

Fibroblast growth factor and nucleic acids encoding same

The present invention is based upon methods of treating inflammatory conditions in the intestinal tract of mammals using growth factor related polypeptides. The invention includes methods of reducing the morality rate or delaying mortality in a subject suffering from an inflammatory pathology. Methods of using fibroblast growth factor-CX (FGF-CX) polynucleotide sequences and the FGF-CX polypeptides encoded by such nucleic acid sequences, or variants, fragments and homologs thereof, are claimed in the invention. Similarly, methods of using FCTRX polynucleotide sequences and the FCTRX polypeptides encoded by such nucleic acid sequences, or variants, fragments and homologs thereof, alone or in combination, are also claimed in the invention. FCTRX collectively refers to any of six variant FCTRX sequences, variously designated FCTR1, FCTR2, FCTR3, FCTR4, FCTR5 and FCTR6.

Methods of prevention and treatment of inflammatory bowel disease

Novel angiogenesis/anti-angiogenesis secreted proteins and the nucleic acid sequences which encode them are disclosed by the present invention.

Nucleotide sequences and amino acid sequences of secreted proteins involved in angiogenesis

Growing community of inventors

Branford, CT, United States of America

Michael Jeffers